The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A novel class of mono-alkylating agents with highly potent and selective tumor cell growth inhibitory activity.
G. A. Piazza
No relevant relationships to disclose
H. N. Tinsley
No relevant relationships to disclose
B. D. Gary
No relevant relationships to disclose
M. R. Knight
No relevant relationships to disclose
N. Li
No relevant relationships to disclose
K. N. Tiwari
No relevant relationships to disclose
W. Zhang
No relevant relationships to disclose
W. R. Waud
No relevant relationships to disclose
L. U. Coward
No relevant relationships to disclose
G. Gorman
No relevant relationships to disclose
A. B. Keeton
No relevant relationships to disclose
R. F. Struck
No relevant relationships to disclose
A. H. Abadi
No relevant relationships to disclose